Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 15

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 15
---
 various extremist groups in the region, such as various rebel militia groups in Syria and Iraq. In October 2024, Israel began limited ground operations against Hezbollah
in Lebanon, and in November 2024, a ceasefire was brokered between Israel and Hezbollah. It is possible that hostilities with Iran, Hezbollah, the Houthis and
Syria will escalate, and that other terrorist organizations, including Palestinian military organizations in the West Bank, will join
the hostilities. In addition, Iran recently launched direct attacks on Israel involving hundreds of drones and missiles, has threatened
to continue to attack Israel, and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence
among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthis in Yemen and various rebel militia groups
in Syria and Iraq. These situations may potentially escalate in the future to more violent events which may affect Israel and us. Any
hostilities, armed conflicts, terrorist activities involving Israel or the interruption or curtailment of trade between Israel and its
trading partners, or any political instability in the region could adversely affect business conditions and our results of operations
and could make it more difficult for us to raise capital and could adversely affect the market price of our ordinary shares. An escalation
of tensions or violence might result in a significant downturn in the economic or financial condition of Israel, which could have a material
adverse effect on our operations in Israel and our business. Parties with whom we do business have sometimes declined to travel to Israel
during periods of heightened unrest or tension, forcing us to make alternative arrangements when necessary in order to meet our business
partners face to face. In addition, the political and security situation in Israel may result in parties with whom we have agreements
involving performance in Israel claiming that they are not obligated to perform their commitments under those agreements pursuant to
force majeure provisions in such agreements.

Since the war broke out on October 7, 2023,
our operations have not been adversely affected by this situation, and we have not experienced disruptions to our clinical studies, facilities
or the manufacturing or supply of our drug candidates. However, the intensity and duration of Israel’s current security situation
in Israel is difficult to predict at this stage, as are such war’s economic implications on our business and operations and on
Israel’s economy in general, and we continue to monitor the situation closely and examine the potential disruptions that could
adversely affect our operations.